Cargando…
GTSE1 expression represses apoptotic signaling and confers cisplatin resistance in gastric cancer cells
BACKGROUND: Platinum based therapy is commonly used in the treatment of advanced gastric cancer. However, resistance to chemotherapy is a major challenge that causes marked variation in individual response rate and survival rate. In this study, we aimed to identify the expression of GTSE1 and its co...
Autores principales: | Subhash, Vinod Vijay, Tan, Shi Hui, Tan, Woei Loon, Yeo, Mei Shi, Xie, Chen, Wong, Foong Ying, Kiat, Zee Ying, Lim, Robert, Yong, Wei Peng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4514980/ https://www.ncbi.nlm.nih.gov/pubmed/26209226 http://dx.doi.org/10.1186/s12885-015-1550-0 |
Ejemplares similares
-
Strategies and Advancements in Harnessing the Immune System for Gastric Cancer Immunotherapy
por: Subhash, Vinod Vijay, et al.
Publicado: (2015) -
Anti-tumor efficacy of Selinexor (KPT-330) in gastric cancer is dependent on nuclear accumulation of p53 tumor suppressor
por: Subhash, Vinod Vijay, et al.
Publicado: (2018) -
GTSE1 is possibly involved in the DNA damage repair and cisplatin resistance in osteosarcoma
por: Xie, Chaofan, et al.
Publicado: (2021) -
Pan-cancer analyses reveal GTSE1 as a biomarker for the immunosuppressive tumor microenvironment
por: Tan, Ke, et al.
Publicado: (2023) -
High GTSE1 expression promotes cell proliferation, metastasis and cisplatin resistance in ccRCC and is associated with immune infiltrates and poor prognosis
por: Lei, Pu, et al.
Publicado: (2023)